Radiopharmaceutical roadmap: iodine → lutetium → actinium
The radiopharmaceutical roadmap runs eighty years from radioactive iodine for thyroid cancer to alpha-emitting drugs for prostate and neuroendocrine cancers, with isotope supply as the limiting factor.
Overview
The radiopharmaceutical roadmap runs from radioiodine curing differentiated thyroid cancer, the first theranostic, through radium-223 and Lutathera with its matched 68Ga-DOTATATE PET, to PSMA PET and Pluvicto building the first radioligand franchise. The current steps move Pluvicto and Lutathera into earlier lines amid an M&A wave, while the emerging step brings 225Ac and 212Pb alpha emitters and new targets such as FAP, GRPR, CAIX and B7-H3 into trials, with isotope supply as the limiting factor. The speculative end imagines radioligands as a standard modality with pan-cancer FAP theranostics and personalised dosimetry. The route links radioligand therapy, targeted alpha therapy, PSMA PET and FAPI PET, prostate, thyroid and neuroendocrine cancers, and the manufacturing bottleneck.
- 1946-2000historic
Radioiodine and early radioimmunotherapy
131I cures differentiated thyroid cancer, the first theranostic. Strontium-89 and samarium-153 palliate bone pain. 90Y-ibritumomab and 131I-tositumomab (2002-03) work in lymphoma but fail commercially.
- 2013-2018historic
Radium-223 and Lutathera
Radium-223 (ALSYMPCA, 2013) is the first alpha emitter approved, for bone metastases. 177Lu-DOTATATE (NETTER-1, 2018) establishes the modern peptide receptor radionuclide therapy paradigm with a matched 68Ga-DOTATATE PET.
- 2020-2022current
PSMA theranostics
PSMA PET approved (68Ga-PSMA-11 2020, Pylarify 2021); Pluvicto approved (VISION, 2022). Novartis builds the first radioligand commercial franchise; supply and site-capacity constraints appear.
- 2023-2026current
Earlier lines, consolidation, and an M&A wave
PSMAfore moves Pluvicto pre-chemotherapy (2025), NETTER-2 moves Lutathera to first line (2024); 2026 label expansions. BMS buys RayzeBio ($4.1B), AstraZeneca buys Fusion ($2.4B), Lilly buys Point; Bayer, Sanofi, Novartis expand. Pylarify TruVu approved March 2026. ITM-11 reads out a positive phase 3.
- 2026-2029emerging
Alpha emitters and new targets
225Ac-PSMA (Novartis, Bayer Trillium, Fusion FPI-2265), 225Ac-DOTATATE (RYZ101) and 212Pb-DOTAMTATE are in phase 3; FAP radioligands (FAP-2286) are in phase 2; GRPR, CAIX, B7-H3, DLL3 radioconjugates are in early trials. TerraPower's Philadelphia Ac-225 plant aims for a 20-fold supply increase. Dosimetry-guided dosing enters trials.
- 2029+speculative40% to 65%likely
Speculative: radioligands as a standard modality
Alpha therapy in hormone-sensitive prostate cancer and after ADC failure; pan-cancer FAP theranostics; radio-ADCs and pretargeting; combination with PARP inhibitors, IO, and ADCs; automated decentralised radiopharmacies; total-body PET for ultra-low-dose dosimetry.
Probability ranges are named estimates that the claim is borne out on roughly a five-year horizon. They are meant to be argued with: propose a revision with your name and reasoning via a pull request to src/data/confidence.ts.
Story
topRadioiodine and early radioimmunotherapy
131I cures differentiated thyroid cancer, the first theranostic. Strontium-89 and samarium-153 palliate bone pain. 90Y-ibritumomab and 131I-tositumomab (2002-03) work in lymphoma but fail commercially.
Radium-223 and Lutathera
Radium-223 (ALSYMPCA, 2013) is the first alpha emitter approved, for bone metastases. 177Lu-DOTATATE (NETTER-1, 2018) establishes the modern peptide receptor radionuclide therapy paradigm with a matched 68Ga-DOTATATE PET.
Lutetium-177 dotatate was the first modern radioligand therapy (2018), for neuroendocrine tumours, and is now used in first line.
Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.
PSMA theranostics
PSMA PET approved (68Ga-PSMA-11 2020, Pylarify 2021); Pluvicto approved (VISION, 2022). Novartis builds the first radioligand commercial franchise; supply and site-capacity constraints appear.
A prostate-cancer-specific PET scan that finds spread far earlier than CT or bone scan, and tells you whether a matched radioactive drug will work.
A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.
VISION was the trial that established radioligand therapy in prostate cancer.
Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026.
Earlier lines, consolidation, and an M&A wave
PSMAfore moves Pluvicto pre-chemotherapy (2025), NETTER-2 moves Lutathera to first line (2024); 2026 label expansions. BMS buys RayzeBio ($4.1B), AstraZeneca buys Fusion ($2.4B), Lilly buys Point; Bayer, Sanofi, Novartis expand. Pylarify TruVu approved March 2026. ITM-11 reads out a positive phase 3.
PSMAfore moved Pluvicto before chemotherapy in prostate cancer.
An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version.
Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.
RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.
ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).
Alpha emitters and new targets
225Ac-PSMA (Novartis, Bayer Trillium, Fusion FPI-2265), 225Ac-DOTATATE (RYZ101) and 212Pb-DOTAMTATE are in phase 3; FAP radioligands (FAP-2286) are in phase 2; GRPR, CAIX, B7-H3, DLL3 radioconjugates are in early trials. TerraPower's Philadelphia Ac-225 plant aims for a 20-fold supply increase. Dosimetry-guided dosing enters trials.
Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.
An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version.
A FAP-targeted theranostic pair: one version images almost any solid tumour, the other treats it with radiation.
Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.
Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).
Measuring how much radiation dose each organ and tumour actually received from a radioactive drug.
Speculative: radioligands as a standard modality
Alpha therapy in hormone-sensitive prostate cancer and after ADC failure; pan-cancer FAP theranostics; radio-ADCs and pretargeting; combination with PARP inhibitors, IO, and ADCs; automated decentralised radiopharmacies; total-body PET for ultra-low-dose dosimetry.
Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy.
After lutetium therapy stops working, an actinium version of the same drug can still produce responses.
PET and CT in one machine, so hot spots on the PET are pinned to exact locations on the CT.
Similar pages
not linked directly; found by shared links- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares TerraPower Isotopes, Orano Med, Actinium-225 DOTATATE, Actinium-225 PSMA agents.
- RoadmapAlpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline
Shares Fusion Pharmaceuticals (AstraZeneca), TerraPower Isotopes, RayzeBio (BMS), Orano Med.
- TechnologyActinium-225 supply: thorium stocks, accelerators and radium targets
Shares TerraPower Isotopes, RayzeBio (BMS), ITM Isotope Technologies Munich, Orano Med.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Lead-212, Dosimetry, Somatostatin receptor 2, Lutetium-177 dotatate.
- BottleneckActinium-225 supply
Shares TerraPower Isotopes, RayzeBio (BMS), Orano Med, Actinium-225 DOTATATE.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Dosimetry, Somatostatin receptor 2, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Dosimetry, Somatostatin receptor 2, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours.